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ABSTRACT
Regulation of the Myostatin Protein in Overload-Induced
Hypertrophied Rat Skeletal Muscle
Paige A. Affleck
Department of Exercise Sciences, BYU
Master of Science
Myostatin (GDF-8) is the chief chalone in skeletal muscle and negatively controls adult
skeletal muscle growth. The role of myostatin during overload-induced hypertrophy of adult
muscle is unclear. We tested the hypothesis that overloaded adult rodent skeletal muscle would
result in reduced myostatin protein levels. Overload-induced hypertrophy was accomplished by
unilateral tenotomy of the gastrocnemius tendon in male adult Sprague-Dawley rats followed by
a two-week period of compensatory overload of the plantaris and soleus muscles. Western blot
analysis was performed to evaluate changes in active, latent and precursor myostatin protein
levels. Significant hypertrophy was noted in the plantaris (494 ± 29 vs. 405 ± 15 mg, p < 0.05)
and soleus (289 ± 12 vs. 179 ± 37 mg, p < 0.05) muscles following overload. Overloaded soleus
muscle decreased the concentration of active myostatin protein by 32.7 ± 9.4% (p < 0.01) while
the myostatin precursor protein was unchanged. Overloaded plantaris muscle decreased the
concentration of active myostatin protein by 28.5 ± 8.5% (p < 0.01) while myostatin precursor
levels were reduced by 17.5 ± 5.9% (p < 0.05). Myostatin latent complex concentration
decreased in the overloaded soleus and plantaris muscle by 15.0 ± 5.9% and 70.0 ± 2.3% (p <
0.05), respectively. These data support the hypothesis that the myostatin signaling pathway in
overloaded muscles is generally downregulated and contributes to muscle hypertrophy. Plasma
concentrations of total and active myostatin proteins were similar in overloaded and control
animals and averaged 8865 ± 526 pg/ml and 569 ± 28 pg/ml, respectively. Tissue levels of BMP1, an extracellular proteinase that converts myostatin to its active form, also decreased in
overloaded soleus and plantaris muscles by 40.4 ± 12.9% and 32.9 ± 6.9% (p < 0.01),
respectively. These data support the hypothesis that local, rather than systemic, regulation of
myostatin contributes to the growth of individual muscles, and that an association exists between
the extracellular matrix proteinase BMP-1 and the amount of active myostatin in overloaded
muscles.

Keywords: myostatin, GDF-8, TGF-β superfamily, BMP-1/tolloid proteinases, BMP-1,
mechanical overload, muscle growth, hypertrophy
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INTRODUCTION
Myostatin is a growth and differentiation factor in the transforming growth factor-β
(TGF-β) superfamily (24). The TGF-β superfamily encompasses the growth and differentiation
factors responsible for embryonic development and maintaining tissue homeostasis in adults
(24). Myostatin, also called growth and differentiation factor 8 (GDF-8), is predominantly
expressed in human embryotic and mature adult skeletal muscle (24). Myostatin is involved in
the regulation of muscle size due to its dual regulatory role: the regulation of the number of
muscle fibers during development (hyperplasia) (19) and the regulation of postnatal muscle fiber
growth (hypertrophy) (19, 34, 36).
Mutations in the myostatin gene (24, 25, 29) result in an inactive protein and increased
muscle mass (aka “double muscling”). In humans and animals without this gene mutation, levels
of the myostatin protein are variable and it acts in a concentration-dependent manner to
negatively regulate muscle growth (19). Myostatin mRNA expression is decreased in most (28,
38), but not all (14), studies evaluating loading of adult skeletal muscle. However, only a handful
of studies have measured active myostatin protein levels. These studies show that the
concentrations of active myostatin protein decrease with aerobic exercise (12). In contrast, active
myostatin protein levels have been shown to either increase or decrease with testosterone
administration (15, 16), depending on the time course and age of subjects. Myostatin undergoes
several posttranslational modifications before becoming an active molecule; thus it is possible
that the regulation of posttranslational changes in myostatin account for the apparent discordance
between myostatin gene expression and protein concentrations.
Myostatin is synthesized as a 376 amino acid precursor protein (24). The 52 kD precursor
myostatin protein includes a 26 kD N-terminal dimer (propeptide), a 12.5 kD C-terminal (active
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myostatin) dimer and a signaling peptide (24). The precursor protein must undergo proteolytic
processing to be released from the cell and to become an active molecule (19, 22). Following
proteolytic processing and secretion the mature myostatin (C-terminal dimer) remains noncovalently bound to the propeptide (N-terminal) in an inactive, latent complex (22, 30). This
myostatin latent complex is thought to be available locally in the extracellular matrix (3) and also
circulates in the blood (40). As long as the protein is in the latent complex, activity of the Cterminal dimer is blocked, and receptor binding of the protein does not occur (22, 30). Once the
C-terminal dimer is proteolytically cleaved from the propeptide and thus activated, myostatin can
bind to the activin type II receptor (either ActRIIA or ActRIIB) (31). Myostatin binding to the
activin receptor initiates an intracellular signaling cascade involving SMAD2/SMAD3 (17, 27).
These SMAD proteins act as intracellular mediators for myostatin signaling as well as regulate
myostatin gene expression in a dose-dependent manner (19).
While altering the amount of myostatin in the precursor form is a first step in regulating
active myostatin levels, the extracellular processing of the latent complex may be even more
important. Several mechanisms are capable of latent myostatin cleavage such as: acid, alkali,
heat, limited proteolysis and incubation by glycosidases (26, 40). The exact mechanism by which
latent myostatin is activated in vivo is unclear; however, recent evidence indicates that BMP1/tolloid proteinases in the extracellular matrix are capable of cleaving and activating the
myostatin latent complex (5, 21, 37).
A reduction in myostatin mRNA expression is associated with conditions that favor
muscle hypertrophy (35). However, reducing extracellular processing of the myostatin latent
complex also promotes muscle hypertrophy (21). The purpose of this study was to create an
overload condition in adult skeletal muscle and thereby induce a change in skeletal muscle
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myostatin protein concentrations. We hypothesize that in overload-induced hypertrophy we will
see decreased active myostatin muscle concentrations with little or no change in circulating
active myostatin concentrations. We also hypothesize that the decrease in skeletal muscle active
myostatin will be associated with a reduction in BMP-1 levels leading to reduced capacity to
convert the latent myostatin complex into its active form. In addition, if extracellular processing
by BMP-1 is an important component of this response we would expect the amount of myostatin
latent complex in circulation and in the muscle to increase.
METHODS
Animals. Eleven adult male Sprague-Dawley (300-350 g) rats were used in this research
study. Animals were housed individually in activity wheel cages (Lafayette Instrument
Company, Lafayette, IN) in the animal care facility at Brigham Young University. They were
kept on a 12 h dark-light cycle in a temperature-controlled environment (21-22°C). Rats were fed
standard rat chow and water ad libitum. All experimental procedures and animal care protocols
were approved by the Institutional Animal Care and Use Committee at Brigham Young
University.
Experimental Design. A compensatory overload model was used to induce hypertrophy
in the rodent skeletal muscle to examine myostatin signaling. The compensatory overload model
was chosen because it produces significant and rapid hypertrophy within 1-6 d (6, 8, 10) as well
as increased amino acid uptake (6, 9), and protein synthesis (7, 18) in the overloaded skeletal
muscles. Animal wheel-running activity was measured 5 d prior to surgery. Each animal
received a gastrocnemius tenotomy surgery on one hindlimb in a randomized fashion and the
opposite hindlimb received a sham (control) surgery. After surgery, the animals were allowed to
recover for 14 d while running wheel activity was monitored. After this overload period the
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plantaris and soleus muscles of the tenotomized hindlimb were harvested (Treatment group:
TEN, n = 11) as well as the plantaris and soleus muscles from the sham operated hindlimb
(Control group: CON, n = 11). The harvested tissue was weighed, flash frozen, and stored at 80°C until analysis of myostatin and BMP-1 protein levels by Western blot occurred.
Wheel-Running Activity. Animal wheel-running activity was measured 5 d prior to
surgery and during the entire 14-day overload period using Activity Wheel Monitoring Software
(Lafayette Instrument Company, Lafayette, IN). Wheel-running totals were downloaded once
every hour during dark cycles (awake) and once every 4 h during light (sleep) cycles. Running
wheel activity was used to monitor running behavior pre- and postsurgery to ensure similar
amounts of activity and thereby mechanical overload during the overload period.
Synergist Tenotomy Surgery. Overload-induced hypertrophy of the plantaris and soleus
muscles was achieved with a unilateral tenotomy of the gastrocnemius tendon. Animals were
given Rimadyl chewable tablets (5mg/kg body weight) 24 h prior to surgery and once every 24 h
for 5 d following surgery. Animals were also administered a subcutaneous injection of
buprenorphine (0.06 mg/kg body weight) immediately prior to surgery and every 6-12 h
postsurgery for 48 h. At the start of surgery, animals were weighed, placed on a heating pad and
anesthetized with 2-3% isoflurane and supplemental oxygen. Animals were anesthetized
throughout the surgery and the depth of anesthesia was monitored with a pedal reflex. The skin
on the posterior side of each hindlimb was shaved and cleaned with vetadine solution. Under
sterile conditions, a 1 cm incision was made at the myotendinous junction of each hindlimb. The
fascia surrounding the incision was separated using blunt dissection. The medial and lateral
heads of the gastrocnemius were isolated, spliced and sutured back into the muscle belly in
hindlimbs receiving a tenotomy surgery. In control hindlimbs, the gastrocnemius attachments
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were isolated but remained intact to allow normal function of the gastrocnemius muscle during
the overload period. All incisions were closed with two 9 mm MikRon stainless steel surgical
clips. Each animal’s pain, distress and activity levels were monitored and recorded for seven d
following surgery.
Harvesting Tissue. Fourteen days after surgery, animals were weighed and anesthetized
with 2-3% isoflurane and supplemental oxygen. The skin surrounding the ankle was removed
and blunt dissection used to separate the fascia from skeletal muscle. The gastrocnemius (medial
and lateral heads), plantaris, soleus and heart were harvested, immediately weighed and flash
frozen in liquid nitrogen. Harvested muscles were stored in -80°C until analyzed.
Blood Sample. A 2 mL blood sample was drawn from each animal during tissue
harvesting and placed in cooled EDTA vacutainers. Blood samples were centrifuged at 3000 rpm
for 15 min at 3°C and the plasma separated and stored in -80°C until analyzed.
ELISA. Total plasma myostatin concentrations were measured using an antibody
sandwich enzyme-linked immunosorbent assay (ELISA) kit (Quantikine: R&D Systems
Minneapolis, MN). To isolate active plasma myostatin, plasma samples were filtered through a
30 kD Micro Bio-Spin Chromatography Column (Bio-Rad Laboratories, Inc., Hercules, CA).
The filtering of these plasma samples resulted in a retention of the larger latent and precursor
myostatin proteins in the column but allowed the smaller (26 kD) active myostatin molecule to
be collected in the filtrate. Circulating inactive myostatin was estimated by subtracting the
measurement of active myostatin protein from the measurement of total myostatin in plasma.
Homogenization. Whole muscle samples were powdered with mortar and pestle under
liquid nitrogen. Approximately 50 mg of powered muscle was then homogenized (9 ml/mg) on
ice 2 x 30 sec in a homogenization buffer (50 mM tris-HCL, pH 7.4; 250 mM mannitol; 50 mM
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NaF; 5 mM sodium pyrophosphate; 1 mM EDTA; 1 mM EGTA; 1% Triton X-100; 50 mM βglycerophosphate; 1mM sodium orthovanadate; 1 mM DTT; 1 mM benzamidine; 0.1 mM
phenylmethane sulfonyl fluoride; 5 µg/ml soybean trypsin inhibitor) containing a protease
inhibitor mix (1 M DTT (dithiothrietol), 1 M benzamidine, 5 ug/ul STI (soybean trypsin
inhibitor), 200 mM Na3Vo4 (sodium orthovanadate), 200 mM PMSF (phenylmethane sulfonyl
fluoride)). Homogenates then underwent three cycles of freeze/thaw lysis, after which they were
centrifuged at 16,000 x g for 10 min at 4°C. Total protein concentration of the supernatant was
determined and the supernatant was aliqouted into eppendorf tubes and stored at -80°C until
analysis.
Total Protein Analysis. Total protein concentration of homogenates was determined using
a DC (detergent compatible) Protein Assay (DC Protein Assay Kit, Bio-Rad Laboratories, Inc.,
Hercules, CA). Absorbance was measured on a micro plate reader (VICTOR3, PerkinElmer and
Analytical Sciences, Shelton, CT) at a wavelength of 750 nm.
Western Blotting. Samples were electrophoresed under reducing conditions by adding 5%
β-mercaptoethanol to sample buffer and boiling samples for 10 min. Each homogenate was
loaded into the wells of a 12% TGX Criterion gel (Bio-Rad Laboratories, Inc., Hercules, CA) at
a total protein content of 40 ug. Treatment and sham samples of each animal were loaded into
neighboring lanes of the same gel. Proteins were separated at 200 V for 50 min. A molecular
weight ladder (Precision Plus Protein All Blue Standards, Bio-Rad Laboratories, Inc., Hercules,
CA) and 50 ug of a positive control (Myostatin: Recombinant Human/Mouse/Rat GDF8/Myostatin R&D Systems, Inc., Minneapolis, MN. BMP-1: NIH/3T3 Whole Cell Lysate Santa
Cruz Biotechnology Inc., Santa Cruz, CA) were included on each gel.
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Transfer. Proteins were electrotransferred onto a polyvinylidene difluoride (PVDF)
membrane in chilled Tris/Glycine transfer buffer for 1 h at 100 volts. Protein transfer to
membrane was confirmed with a Ponceau S Stain.
Myostatin (GDF-8). Membranes were first blocked in 3% BSA (bovine serum albumin)
in TBS-T (TBS pH 7.4 + 0.1% Tween-20) for 1 h. They were then incubated in primary
antibody; a polyclonal goat IgG (AF788, R&D Systems, Inc., Minneapolis, MN) diluted 1:1000
in 0.1% BSA in TBS-T for 1 h (13). The AF788 antibody targets the carboxy-terminal region
(Asp268Ser376) of the myostatin molecule and therefore is able to identify all three forms of
the protein (precursor, latent, and active myostatin) in skeletal muscle (13). Membranes were
rinsed vigorously twice for 15 min with TBS-T. Lastly, they were incubated in a goat IgG
Horseradish Peroxidase-conjugated secondary antibody, diluted 1:5000 in TBS-T for 30 min. All
steps were performed at room temperature.
BMP-1. Membranes were blocked 1 h in 5% non-fat dry milk in TBS-T (TBS pH 7.6 +
0.1% Tween-20). They were incubated 1 h in primary antibody; a rabbit polyclonal [BMP-1 (H300), Santa Cruz Biotechnology Inc., Santa Cruz, CA)] diluted 1:200 in 1% milk in TBS-T.
Membranes were rinsed vigorously three times, 5 min each in TBS-T. Lastly, they were
incubated in secondary antibody; a goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) diluted 1:4000 in 1% milk in TBS-T for 45 min. All steps were performed at
room temperature.
GAPDH. GAPDH was measured on each membrane as a loading control. Previously
incubated gels were stripped with an 8 min incubation in stripping buffer (0.2 M glycine, 10%
tween, 0.1% SDS, pH 2.2) at 37°C, one 5 min wash at room temperature in TBS-T, another 8
min incubation in 0.2 M NaOH at 37°C, then followed by 2 x 5 min washes in TBS-T at room
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temperature. Once previous bound antibodies were stripped, the membranes were blocked in 3%
BSA for 1 h at room temperature and then incubated 1 h in primary antibody; a goat polyclonal
[GAPDH (I-19), Santa Cruz Biotechnology Inc., Santa Cruz, CA)] diluted 1:10,000 in 0.1%
BSA in TBS-T. Following primary incubation, the gel was rinsed three times, 5 min each in
TBS-T and incubated in a rabbit anti-goat IgG-HRP secondary antibody (Santa Cruz
Biotechnology Inc., Santa Cruz, CA) diluted 1:30,000 in 0.1% BSA in TBS-T for 30 min at
room temperature.
Analysis. Chemiluminescence detection solution was applied to each blot and incubated
for 5 min according to the manufacturer’s instructions (Clarity Western ECL Substrate, Bio-Rad
Laboratories, Inc., Hercules, CA). An image of each blot was then taken using a ChemiDoc XRS
CCD camera-based imager (Bio-Rad Laboratories, Inc., Hercules, CA). Quantitative protein
analysis of each band was performed using the Quantity One Software version 4.6.5 (Bio-Rad
Laboratories, Inc., Hercules, CA). Samples were run in duplicate on separate gels and the two
measurements were averaged and then normalized to the expression of GAPDH.
Statistical Analysis. Standard statistical procedures were used to calculate the means and
standard errors. A paired t-test was used to compare specific protein levels in treatment and sham
legs of each animal. An analysis of variance (ANOVA) was used to compare plasma myostatin
measurements of animals that received the overload treatment and cage control animals. Animal
wheel-running activity pre- and postsurgery was analyzed using a Dunnett’s test. Results were
presented as mean ± SEM. Differences between the means were regarded as significant when a
value of p < 0.05 was obtained.
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RESULTS
Figure 1 illustrates the free wheel-running behavior of the rats 5 d prior and 14 d posttenotomy. Rats typically increased their running distance per day when first placed in the
individual cages containing the running wheels. On the day just prior to tenotomy surgery (day-1,
Figure 1) animals ran an average distance of 4750.7 ± 552.5 m. Following tenotomy surgery, the
daily running distance dropped significantly but returned to distances seen prior to tenotomy by
day 4 and by day 14 post-tenotomy animals ran an average distance of 5491.09 ± 665.96 m.
The overloaded muscles showed significant hypertrophy as shown in Figure 2. Following
two weeks of overload both the plantaris (494 ± 29 vs. 405 ± 15 mg, p < 0.05) and soleus (289 ±
12 vs. 179 ± 37 mg, p < 0.05) muscles increased in weight while the gastrocnemius weight on
the tenotomy leg atrophied (p < 0.05).
Overloaded soleus and plantaris skeletal muscle reduced the concentration of active
myostatin protein by 32.7 ± 9.4% and 28.5 ± 8.5%, respectively (p < 0.01, Figure 3). Latent
myostatin protein also decreased by 15.0 ± 5.9% and 7.0 ± 2.3% (p < 0.05) in overloaded soleus
and plantaris muscle, respectively. Precursor myostatin protein concentration was reduced 17.5 ±
5.9% in the overloaded plantaris muscle (p < 0.05) and was unchanged in overloaded soleus
muscle.
Following 14 d of overload, the soleus and plantaris muscles decreased levels of the
proteinase BMP-1 by 40.4 ± 12.9% and 32.9 ± 6.9% (p < 0.01, Figure 4), respectively.
Circulating plasma myostatin levels are shown in Figure 5. Plasma concentrations of total
and active myostatin proteins were similar in overloaded and control animals and averaged 8865
± 526 pg/ml and 569 ± 28 pg/ml, respectively. In plasma, active myostatin represented 6.5 ±
0.2% of the total circulating myostatin.
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DISCUSSION
Myostatin is located in two pools: the extracellular matrix of skeletal muscle (local pool)
and circulating in the blood (systemic pool) (3, 21, 40). Regulation of the myostatin protein
during muscle growth, in either of these locations, is not fully understood. Using an overload
model, we measured myostatin protein levels to better understand regulation of the myostatin
protein during muscle growth.
Following overload-induced skeletal muscle growth, concentrations of all forms of local
myostatin (precursor, latent and active) were decreased when compared to the nonoverloaded
muscle. In addition, the proteinase regulator that converts the myostatin latent complex to its
active form, BMP-1, was reduced in overloaded skeletal muscles. These data indicate a general
reduction in levels of myostatin proteins during overload-induced skeletal muscle hypertrophy
and a reduction in the capacity to convert latent myostatin complex into its active form by BMP1.
Myostatin is expressed in the precursor form and proteolytically processed into the latent
and active protein forms. Conversion to latent myostatin is the first posttranslational
modification and is necessary for downstream signaling (19). Previous studies have shown that
processing of precursor myostatin is a key regulatory step in the myostatin signaling pathway
and occurs in the bloodstream and in the muscle (3, 23). Levels of precursor myostatin were
significantly decreased in overloaded plantaris muscle (Figure 3) and tended to be reduced in
overloaded soleus muscle when compared to control muscles. These results confirm the findings
of Anderson et al. (3) and McFarlane et al. (23) demonstrating that the precursor protein is one
point in the pathway where muscle myostatin is regulated during muscle growth. More
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importantly, our data demonstrate this regulatory pathway is operating during functional
overload in adult skeletal muscle.
The latent form of the myostatin protein is a second point of protein regulation. Latent
myostatin is a complex consisting of the active protein and a propeptide. Myostatin is inactive in
the latent form and receptor binding does not occur until the propeptide is removed. Several
factors which cleave the propeptide in vitro include heat, alkali or acid. However, in vivo,
cleavage can occur via extracellular matrix proteinases (37). Animals with higher concentrations
of circulating latent myostatin have greater muscle mass (19, 39). Lee et al. (21) altered the
myostatin gene of a mouse resulting in the production of a propeptide that could not be cleaved
by extracellular matrix proteinases in the BMP-1/TLD family (21). These animals exhibited
significant muscle hypertrophy with increased amounts of circulating latent myostatin protein
compared to wild type mice. These animals exhibited significant muscle hypertrophy with
increased amounts of circulating latent myostatin protein compared to wild type mice. These
authors concluded that the increased muscle mass was a result of a reduction in latent myostatin
being cleaved to its active form. Latent myostatin in the muscle was however not measured in
the transgenic animals. Based on the findings of Lee et al. we hypothesized that following an
overload stimulus skeletal muscle latent myostatin would increase. Contrary to this hypothesis
we show a decrease in latent myostatin in overloaded muscles (Figure 3). To our knowledge, no
previous studies have measured skeletal muscle latent myostatin following overload-induced
muscle growth. Therefore, these data appear to contribute new evidence of how the latent
complex functions in the muscle during muscle growth.
Once the propeptide is removed from the latent complex, myostatin becomes an active
protein (20). Active myostatin binds to target cell receptors and initiates a signaling cascade
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inside the cell that inhibits muscle cell growth pathways (2). Active myostatin exerts its
inhibitory effects in a concentration-dependent manner. As such, to increase skeletal muscle
mass there must be a reduction in the amount of active myostatin (20). The majority of myostatin
literature related to skeletal muscle growth is comprised of studies that measured myostatin
mRNA expression. Our data show that active myostatin protein was significantly decreased
(Figure 3) in overloaded plantaris and soleus muscles. These data provide further evidence that
active myostatin protein levels are reduced during mechanical overload muscle growth, and
suggests that reducing the amount of active myostatin protein at a muscle site may be one way to
stimulate muscle growth in overloaded skeletal muscles.
Previous studies have provided evidence of myostatin functioning both systemically and
locally (3, 4, 21). Increasing the amount of circulating myostatin causes muscle wasting
throughout the body, indicating the protein’s systemic effect (40). Lee et at. (21) reported that the
majority of circulating myostatin protein in mice was in the latent form and suggested that the
circulating form of myostatin was most important in regulating muscle growth (systemic effect).
Anderson et al. (3) demonstrated that circulating myostatin is able to enter and accumulate in the
muscle’s extracellular matrix, and suggested that local mechanisms activate latent myostatin and
eventually control individual muscle growth (local effect). We measured muscle and plasma
myostatin levels in an effort to understand the relationship between circulating and muscle
myostatin and its impact on muscle growth during functional overload. Based on the findings of
previous studies, if muscle growth was regulated primarily by circulating myostatin then the
amount of circulating latent myostatin should increase during functional overload (11, 21).
Total myostatin and active myostatin protein were measured in the plasma of animals
following two weeks of unilateral hindlimb overload and compared to plasma measurements of
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cage control animals that did not receive the overload treatment. We found no differences in
plasma myostatin protein levels (Figure 5) in overloaded and control animals. It is possible that
circulating myostatin levels only reflect myostatin leaking from muscle pools and have no
regulatory role. Instead, during overload the effects of circulating myostatin are mediated locally
at the muscle cell (20). Our data appear to support this speculation. However, it is also possible
that the overload stimulus in our unilateral model was insufficient to produce significant changes
in circulating myostatin levels.
A body of literature has demonstrated in vitro that all four proteinases of the bone
morphogenetic protein-1/tolloid (BMP-1/Tolloid) family of metalloproteinases (BMP-1, mTLD,
mTLL-1 and mTLL-2) cleave latent myostatin into the active protein (5, 37). However,
identification of the specific proteinase or combined proteinases involved in this conversion
process in vivo is unclear. Greenspan et al. (5) performed an analysis of the four proteinases’
activity in neural, bone and skeletal muscle mammal tissues. Based on their findings, we
concluded that the proteinase BMP-1 from the BMP-1/TLD family would be the proteinase in
adult skeletal muscle responsible for regulating the conversion of latent myostatin to the active
protein. Overloaded soleus and plantaris muscles showed significant reductions in the
concentration of the proteinase BMP-1 (Figure 4). As previously discussed, active myostatin
protein also decreased in the overloaded muscles. These measurements together provide
evidence of an association between the proteinase BMP-1 and the amount of active myostatin in
an individual muscle. The data presented here supports the idea that both myostatin pools,
systemic and local, are regulated locally at the muscle cell level. In addition, reduced activity of
the proteinase BMP-1, found in the in the extracellular matrix, contributes to local myostatin
regulation.
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It has previously been demonstrated that myostatin mRNA expression decreases in an
overload model (38) and increases with unloading (1, 33). However, transcription data only
roughly describes protein activity and changes at the gene expression level are not always
correlated with changes in protein concentration (32). This may be especially true for the
myostatin protein pathway because the active myostatin protein accounts for only 6.5% of the
total circulating myostatin and undergoes several posttranslational modifications before
becoming active. Current literature suggests that myostatin protein modifications are part of a
complex regulatory system. Myostatin is released from the producing cell and distributed to
individual muscles via circulation. Currently, the regulation of myostatin involved in the growth
of individual muscles is not fully understood. Two theories have been presented: regulation of
circulating myostatin and regulation of muscle myostatin.
This study examines the distribution of myostatin proteins, active, latent and precursor, in
muscle and plasma following two weeks of overload-induced adult muscle growth. Our data
demonstrates decreased concentrations of precursor, latent and active myostatin in overloaded
muscles with no change in total, latent and active circulating myostatin. Based on these data, it
appears that the myostatin signaling pathway in overloaded muscles is generally downregulated
and contributes to muscle hypertrophy. Our data show decreased concentrations of BMP-1 and
active myostatin in overloaded muscles. This supports the concept of local control of
posttranslational modification of myostatin in regulating muscle growth during functional
overload. Based on these observations, it appears that local targeting of posttranslational
myostatin protein may be one way to increase muscle growth of individual muscles during states
of disease, disuse and aging.
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